BactoAI in the media.
Coverage of our work on antimicrobial resistance, plus a press kit and a direct media contact for journalists, event organisers, and partners.
Bringing the AMR conversation to national television.
BactoAI founder Samwel Elegwa joined KUTV Kenya’s Art & Culture Monday to talk about antimicrobial resistance and why faster, genome-driven diagnostics matter for patients, clinicians, and public health systems.
“AMR is not just a lab problem. It is a public health emergency that needs to be part of everyday conversation.”

Samwel with Hassan Lewa at the KUTV studio after the Art & Culture Monday interview.
Representing BactoAI at the BIK Ventures Hub pitch event.
In May 2026, Samwel Elegwa and William Otieno represented BactoAI at the BIK Ventures Hub startup pitch event at Kenyatta University, a landmark competition bringing together founders, investors, and industry leaders. The event was covered in print and on BIK’s YouTube channel.

Press coverage of the BIK Ventures Hub pitch event at Kenyatta University, where BactoAI took the stage among East Africa’s emerging startups.
Samwel shares his feedback on the BIK Ventures experience and what it means for startups building in East Africa.
BIK’s recap video features the event’s innovations, including BactoAI.
Everything you need to write about us.
Logo & wordmark
The BactoAI wordmark with the bacterial emblem, for use in articles and event material. Please keep clear space around it and don't recolour it.
Download logo (PNG)Company one-pager
A concise overview of the platform, our validation approach, and current pilot opportunities. Available on request while we finalise the public version.
Request one-pagerInterviews & expert comment
Our founder and team are available for interviews and background briefings on antimicrobial resistance, genomic diagnostics, and health innovation in East Africa.
Request an interviewBactoAI is a Kenyan health-technology company building an AMR intelligence platform that predicts antimicrobial resistance directly from bacterial genomes, helping clinicians and laboratories reach the right treatment decision faster. The platform is built and owned by BactoAI as a company, combining biotechnology, software engineering, machine learning, operations, and partnerships expertise.
Talk to the BactoAI team.
For interviews, event invitations, data requests, or fact-checking, email us directly. We usually reply within two working days.

